ClinicalTrials.gg
RecruitingNCT05805449BIO RAMPUpdated Apr 10, 2023

BIOlogic Augmented Repair of Complex Anal Fistula Using Acellular Matrix and/or Autologous Platelet-rich Plasma

An interventional study of Surgery and Platelet-rich plasma (PRP) in Anal Fistula, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-10.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Rectal Fistula with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Rectal Fistula · United States.

Planned enrollment
2nd of 15
250 · median 21
Started
2023
with 1 other
No phase
8 of 20
3 open now
Registered
14th of 20
by date

Among the 20 studies in Rectal Fistula with a site in United States, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 with no phase, and was the 14th registered.

Rectal Fistula

170 studies on the registry are indexed under Rectal Fistula; 45 are open to participants now.

Browse Rectal Fistula studies →

Open to participants now

7 of the 20 studies in Rectal Fistula with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Rectal Fistula studies recruiting now, 18 (69%) set no upper age limit and 7 (27%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Rectal Fistula with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the clinical effectiveness of augmenting surgical repair of complex anal fistula using autologous PRP and/or micronized acellular porcine urinary bladder matrix (UBM) to usual surgical care alone to prevent fistula recurrence or improve HRQoL, to compare the effects of augmenting surgical repair of complex anal fistula using autologous PRP and/or micronized acellular porcine urinary bladder matrix on early postoperative pain and fecal continence and to assess the cost utility of augmented complex fistula repair relative to usual surgical care

03

Conditions studied

  • Anal Fistula

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • complex cryptoglandular transsphincteric anal fistula undergoing surgical repair by LIFT or advancement flap procedure
  • English or Spanish speaking and capable of providing
  • Willing to undergo temporary anal seton drainage for requisite time prior to repair
  • Participating surgeons will only be eligible if they perform at least 3 repair procedures/year

Exclusion criteria

Exclusion Criteria:

  • Unable to reliably complete follow up for 12 months postoperatively
  • Primary disorders
  • Thrombocytopenia \< 150 plt/microliter
  • Inability to stop anti-platelet agent > 5 days preoperatively
  • Fistula associated with inflammatory bowel disease (IBD), or pelvic/perineal radiation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Sham comparator
    Surgery

    Control patients will receive usual standard of care surgical repair of their complex fistula by The ligation of intersphincteric tract (LIFT) or advancement flap technique without any biologic adjunct.

    Procedure: Surgery

  • Experimental
    Surgery plus platelet-rich plasma (PRP)

    Procedure: Surgery · Other: Platelet-rich plasma (PRP)

  • Experimental
    Surgery plus matrix

    Procedure: Surgery · Device: Matrix

  • Experimental
    Surgery plus PRP plus matrix material

    Procedure: Surgery · Other: Platelet-rich plasma (PRP) · Device: Matrix

Interventions

  • ProcedureSurgery

    Control patients will receive usual standard of care surgical repair of their complex fistula by LIFT or advancement flap technique without any biologic adjunct.

  • OtherPlatelet-rich plasma (PRP)

    Participants will have 40-50cc of peripheral whole blood drawn into a syringe pre-loaded with acid citrate dextrose (ACD) anticoagulant and concentrated PRP harvested by double centrifugation technique using the manufacturer's kit and benchtop centrifuge. This typically yields 5-8cc of PRP that is 18-times more concentrated than baseline.

  • DeviceMatrix

    Participants will receive 200g of "paste" matrix and 200g injected at the following sites: the internal opening closure site at level of the sphincter muscle, within the walls of the fistula tract along its length, and within the tissue of an advancement flap particularly at areas of tissue apposition.

06

What researchers measure

Primary outcomes

  1. Number of participants with fistula recurrence

    A fistula recurrence is defined as one or more of the following clinical signs or symptoms after repair: recurrent abscess at the site of repair, chronic drainage or passage of flatus from an external opening of the perineum away from the anal verge, a non-healing external opening that tracks toward anus by probing with fistula probe.

    Time frame: upto 6 months after surgery

  2. Change in Health-related quality of life (HRQoL) as assessed by the EQ-5D-5L questionnaire

    This instrument queries subjects on health status related to mobility, self-care, 'usual' activities, pain/discomfort, and anxiety/depression with 5 potential responses ranging from "no problems" to inability to complete the task or extreme levels of pain/depression, correlating to a discrete index score from 1-5, a higher number indicating a worse outcome.The instrument also includes an overall VAS self-rating of health ranging from 0-100, higher number indicating better health.

    Time frame: Baseline, 1week post surgery, 2 weeks post surgery, 6 weeks post surgery, 3 months post surgery, 6 months post surgery, and 12 months post surgery.

Secondary outcomes

  1. Number of participants who have post operative pain as assessed by the visual analog scale (VAS)

    This is scored from 0-100, higher number indicating better health

    Time frame: 14 days after surgery

  2. Change in fecal continence as assessed by the Cleveland Clinic Fecal Incontinence (CCFI) scoring tool

    This is a 5 item questionnaire that assesses type of incontinence (solid, liquid, gas, wears pad, lifestyle alteration). The frequency with which each type of incontinence occurs is rated on a scale from 0 (never) to 4 (always or to 1/day). The sum of the frequencies is added to yield a total score that can range from 0 to 20, with higher scores indicating higher levels of incontinence.

    Time frame: Baseline, 2 weeks after surgery,6 weeks after surgery,3 months after surgery,6 months after surgery and 12 months after surgery

  3. The relative cost utility of the different treatment strategies as assessed by a questionnaire

    A cost effectiveness analysis (CEA) will be done from the healthcare system perspective assessed as the incremental health system costs (or savings) per fistula recurrence prevented

    Time frame: 12 months after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Feb 2026, 36 months after the start.

Of 54 non-industry interventional studies with no phase under Rectal Fistula, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 36. This study's planned 36 months is above that.

Counting every sponsor, half of 58 studies reached it within 27 months; a quarter within 11 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
Apr 10, 2023
StartActual
Feb 21, 2023
Primary completionEst.
Feb 28, 2026
CompletionEst.
Mar 31, 2026
Last update
Apr 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05805449
Collaborators
CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCES
Responsible party
Jeff Van Eps, MD (Assistant Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Apr 10, 2023
Start date
Feb 21, 2023
Primary completion
Feb 28, 2026 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Apr 10, 2023

Study contacts

Jeffrey L Van Eps, MD
Contact
Jeffrey.L.VanEps@uth.tmc.edu
713-486-4600
Angielyn Rivera
Contact
Angielyn.R.Rivera@uth.tmc.edu
713-416-1350
Jeffrey L Van Eps, MD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion